Introduction: Concurrent chemoradiation is the standard treatment for the locally advanced cervical cancer. The optimal Cisplatin dose and dosing schedule are still undetermined. The present study aims to evaluate the efficacy and toxicity of weekly and tri-weekly cisplatin with radiotherapy in treatment of cervical cancer.
INTRODUCTION
Current standard treatment for locally advanced cervical cancer is cisplatin-based concurrent chemoradiation. On the basis of the results of five randomized clinical trials, which consistently showed improved survival in patients treated with cisplatin-based chemoradiation, the U.S. National Cancer Institute (NCI) announced in 1992 that " Strong consideration should be given to the incorporation of concurrent cisplatin-based chemotherapy with radiotherapy in women who require radiotherapy for [1] [2] [3] [4] [5] treatment of cervical cancer".
Although recently reported meta-analyses also demonstrated improved local control rates and survival with cisplatin-based chemotherapy concurrent with radiation, the optimal cisplatin dose and dosing schedule [6] [7] [8] are still undetermined. Among the previous five randomized clinical trials, two trials performed by the Gynecologic Oncology Group (GOG) used weekly 2 cisplatin 40 mg/m , whereas the other three trials used Original research article 2 2 triweekly cisplatin at a dose range of 50 mg/m to 75 mg/m [1] [2] [3] [4] [5] combined with 5-fluorouracil (5-FU).
The present study aims to compare two dosing schedules of cisplatin (weekly versus tri-weekly), in terms of efficacy and toxicity, administered to the patients undergoing radiotherapy for cervical cancers.
MATERIAL AND METHODS
All fifty patients of cancer cervix were, biopsy proven; age >18 years; karnofsky performance scale above 70; FIGO stage upto IIIB with no history of previous malignancy. Patients of carcinoma cervix FIGO stage IV and metastatic disease were excluded from the study.
Pre-treatment evaluation was done by complete medical and physical examination, including bimanual pelvic and rectal examination. Other investigations included were hematological tests (haemogram, renal function tests, and liver function tests); chest radiography; ultrasound abdomen or CECT abdomen and pelvis (whichever was Clinical response assessment was done during radiotherapy and every month after radiotherapy for at least 6 months. The patients were assessed for objective tumor response according to WHO criterion: Complete response (CR; total tumor regression for at least 4 weeks), Partial response (PR; 50% or more reduction in two major perpendiculars of the measurable tumor for at least 4 weeks), Stable disease (SD; Less than 50% or more reduction to less than 25% increase), Progressive disease (PD; Growth of measurable tumor by 25% or more or appearance of new lesion).
Patients were assessed weekly during chemo-radiation for acute radiation reactions. Complete blood counts, kidney function tests and liver function tests were repeated in all patients every week before each chemotherapy cycle. Radiation toxicity was assessed by RTOG acute and late morbidity scoring criteria. Hematological toxicities were graded according to common toxicity criteria 2.
Follow up in all the patients were done up to at least 6 months, from the day of completion of treatment.
Statistical analysis was done by Chi square test.
RESULTS
The mean age of the patients was 45 years (range 21-70 years). There was higher incidence of cancer cervix in post menopausal and multiparous women. Most the patients were FIGO stage IIB (46%) and IIIB (22%). On histopathology, forty eight patients had squamous cell carcinoma and only 2 patients in ARM-B were adenocarcinoma ( Table-1 ).
Most common symptom was yellowish/whitish discharge (80% patients) followed by bleeding P/V (58%), common in elderly women (Fig-1) . Hemoglobin was maintained throughout the treatment by blood transfusion, oral hematinics and the dietary advice. Grade II leukopenia was higher in Arm-B then Arm-A (16% Vs 4%), but statistically not significant (p = 0.15). No grade-IV leukopenia was found in either arms. There was no thrombocytopenia seen in both the groups (Table-3 ).
Grade II toxicity vomiting was higher in Arm-B then Arm-A, 60% Vs 24% and it was significant (p = 0.009). No grade IV toxicity seen in both Arms. No significant episodes of diarrhea or genito-urinary symptoms were seen in either arm. (Table-3 ).
Complete tumor response at the end of the treatment was seen in 24 (96%) and 21 (84%) patients in Arm-A & -B, whereas partial response was seen in 4 (16%) in tri-weekly and 1 (4%) in weekly arm (p = 0.15). (Table-4) At the end of six months complete response was seen in 24 patients (96%) in Arm-A and 23 (92%) patients in Arm-B.
Partial response was seen in 2 patients (8%) in Arm-B and 1 patient (4%) in Arm-A showed progressive disease.
No significant late reactions were seen in terms of haematological toxicity, urine infection, vaginal discharge or vaginal mucositis.
DISCUSSION
Chemoradiotherapy in cervical carcinoma is thought to exert its major beneficial effects by improving local control 7 but it also has a modest systematic effect.
In designing chemotherapy protocols, it is critical to note the extreme importance of avoiding delays in the delivery of radiation, a factor well established to negatively impact the ultimate outcome of patients with cervix cancer. Thus, the toxicity profile of any chemotherapy program must permit radiation administration without delay.
While a number of cisplatin-based regimens have been explored, and a definitive statement regarding an "optimal" chemo-radiation approach is not possible, many investigators currently recommend the administration of Hematological toxicities & acute reactions during treatment like leukopenia was significantly more common and more severe in the tri-weekly arm whereas there were no statistical differences in the incidence levels of vomiting, diarrhoea, dermatitis and anemia between the two arms. Our observations are similar to that of 9, 10 Chumworathayi B et al and Lee et al.
Watanabe et al conducted a study as a phase I, doseescalation trial. Concurrent CDDP was started at the dose of 2 2 30 mg/m for the weekly schedule and at 50 mg/m for the monthly schedule, and the doses were steadily escalated to 11 the maximum tolerated dose (MTD). A total of 45 patients with uterine-cervix carcinoma (25 receiving primary chemoradiation (CCRT) and 20 receiving adjuvant CCRT) were entered in the study. In both the primary and adjuvant 2 CCRT patients, the MTD was observed to be 40 mg/m for 2 the weekly schedule and 80 mg/m for the monthly schedule. Dose-limiting toxicity was observed in 10 patients (granulocytopenia in 9 patients and diarrhoea in 1 patient). In the present study all the patients in ARM-B was able to complete the chemotherapy cycles in comparison of ARM-A. Grade III leukopenia was noted in 2 (8%) and there was no grade IV leukopenia found in both the ARMs of our study and it was easily manageable.
Tangsiriwatthana et al noted that grade III and IV hematological toxicities were found in 6% of the patients, 12 who were treated with pelvic radiotherapy. In our study no grade IV hematological toxicities were noted and 1 (4%) patient in ARM-A and 2 (8%) had leukopenia in ARM-B and this data is similar to this study. mg/m (Day 1) and irinotecan at 70 mg/m (Days 1 and 8) were performed. Grade III or IV neutropenia was noted in 12 patients, and 4 patients had grade III or IV anaemia. Their data indicated that the tri-weekly cisplatin and irinotecan combination neo-adjuvant chemotherapy involves only controllable toxicity and yields a high response rate, suggesting that this combination is a useful therapy regimen. Our study was done on the basis of single 2 chemotherapy agent, i.e cisplatin 75 mg/m (which is ARM-B). There was no grade III or IV anemia found in any of the patient and no grade grade IV leukopenia. Only 2(8%) patients had grade III leukopenia.
Chumworathayi B et al. reported that the toxicity-related incomplete treatments rate and G-CSF doses used were significantly higher in tri-weekly arm than in the weekly 9 arm. And the same was noted in our study that 4 (16%) and 2 (8%) patients had grade II and III leukopenia and had to receive G-CSF, to continue the further treatment. Acute-phase vomiting after cisplatin treatment is thought to be primarily mediated via the serotonin receptors, and is nearly universal. In the present study majority of the patients in both the arms (11 in weekly arm and 22 in triweekly arm) had grade I or II vomiting, while only 1 patient in tri-weekly arm had grade 3 vomiting; these changes were not statistically significant.
Tan et al. conducted an audit of acute treatment-related toxicity during chemo-radiotherapy for cervical cancer to 19 assess its tolerance outside research settings. The most common adverse effects were diarrhoea (80.6%), malaise (66.7%) and nausea (62.5%). The most common haematological toxicity was anaemia, with 41.7% patients developing grade I or II toxicity. Only 3 (4.2%) patients had grade III or IV toxicity. These results are similar to present study where anemia is the most common toxicity of grade I or II.
Overall treatment time :
The American Brachytherapy Society recommends keeping the total treatment duration to less than 8 weeks, because prolongation of total treatment duration can adversely affect local control and [20] [21] [22] [23] [24] survival. In this present study, the duration of treatment is almost same (58 days vs 57 days) and did not influence significantly on local control. In ARM-A 25 (100%) patients & 22 (88%) patients in ARM-B completed the treatment within 8 weeks. Only 3(12%) patients in triweekly ARM were extended more than 8 weeks.
The delay in treatment and inability to complete all the chemotherapy cycles was mostly due to adverse effects such as vomiting, diarrhoea, leukopenia and dermatitis or in some cases due to patient compliance related factor.
The follow up time is too short to assess definitively the local control as only response was assessed up to 6 months.
Ryu et al. reported that the two cisplatin-based chemoradiation regimens were tolerated very well, with 86.3% and 92.5% completion rates of scheduled chemotherapy cycles for the weekly and tri-weekly arms, respectively. There was no statistically significant 14 difference of compliance between the two arms (p>0.05).
In our study the completion rate of scheduled chemotherapy in both the groups is statistically significant (p = 0.002).
Chumworathayi B et al while comparing weekly versus three-weekly cisplatin as an adjunct to radiation therapy in high-risk stage I-IIA cervical cancer after surgery reported a higher rate of incomplete and delayed treatments in the tri-weekly cisplatin group (p<0.001 and p=0.0236 9 respectively). In our present study there was delay in treatment in 3 (12%) patients in tri-weekly arm, and it is statistically not significant (p = 0.07). show that pelvic RT combined with weekly cisplatin in cervical cancer patients is a accompanied by considerable acute toxicity. In the present study grade II and III anaemia was seen in 28%. No grade III and IV acute reactions were seen, but grade I and II vomiting in 54%, GIT in 32%, GUT in 4% and dermatitis in 84% was seen and it is being supported by the above study. weekly cisplatin chemotharepy group. They also concluded that the weekly cisplatin chemotherapy group experienced the same therapeutics effect as the tri-weekly combination chemotherapy group but with less toxicity. There were 5 patients in 50 with partial response, 1 in weekly arm and 4 in the tri-weekly arm. 1 patient with partial response in the weekly arm had b/l parametrium involvement (on P/R examination). Whereas, 1 patient with partial response in the tri-weekly arm had unilateral (right) parametrium involvement at the end of 6 months and 3 had ulcerative growth over the cervical lip. This was not statistically significant (p = 0.15).
Singh et al. conducted a prospective randomized study 27 evaluating the role of chemoradiation of fifty patients. The early treatment response as assessed after two months of treatment conclusion were 79.1%, 13.9%, 93.0% and 58.5%, 31.7%, 90.2% as complete response (CR), partial response (PR), and total response (TR) respectively for the study and control groups. In present study 96% CR and 4% PD in weekly arm, whereas 92% CR and 8% PR in triweekly arm and statistically not significant (p = 0.55; CR and p = 0.14:PR). With relatively easier dosage schedule, a better compliance can be expected in the tri-weekly arm, although there was no statistically significantly significant difference between the two arms. 
